This is a technical overview of an INVAMED device within the coronary artery disease & cardiac interventions portfolio. Contemporary practice relies heavily on drug-eluting stents, which release an antiproliferative agent to limit the tissue overgrowth that can cause restenosis. As a medical device manufacturer, INVAMED develops technologies in this area; the information here is educational and not medical advice.
Background: Coronary Artery Disease and Percutaneous Coronary Intervention
The specific combination of wires, balloons, atherectomy, and stents is determined by the interventional cardiologist based on lesion complexity, calcification, and overall clinical picture. During PCI a lesion is usually crossed with a guidewire, prepared with a balloon, and in most cases scaffolded with a stent that holds the vessel open. Coronary artery disease develops when atherosclerotic plaque accumulates within the arteries that supply the heart muscle, gradually narrowing the lumen and limiting blood flow.
Atlas Coronary Stent System Stainless Steel: Overview
Stainless steel variant of the Atlas coronary stent platform for coronary artery lesions.
How It Works and Where It Fits
INVAMED groups its coronary portfolio around the sequence of a PCI case, offering access, lesion preparation, drug delivery, scaffolding, and closure devices. A percutaneous transluminal coronary angioplasty (PTCA) balloon dilates a stenosis to prepare the lesion or to treat it without leaving a permanent implant. A drug-eluting stent combines a thin metallic scaffold with a polymer coating that releases an antiproliferative drug into the vessel wall over time.
Key Considerations
- Guide extension catheters can provide the backup support needed to deliver devices in tortuous or distal anatomy.
- Lesion calcification is a central factor in planning, and heavily calcified plaque may call for rotational atherectomy before ballooning or stenting.
- Dual antiplatelet therapy duration is individualized to the clinical presentation and the patient's bleeding risk.
Frequently Asked Questions
What is the reported restenosis performance of the ATLAS DES?
INVAMED reports clinical data showing target lesion revascularization rates below 5% at 12 months; this reflects studied performance and is not an individual guarantee.
What is the regulatory status of these coronary devices?
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.
What drug does the ATLAS stent release?
According to INVAMED, the ATLAS DES elutes sirolimus at 1 microgram per square millimeter with a sustained controlled-release profile.
Clinical and Technical Context
INVAMED's ATLAS Drug Eluting Coronary Stent System uses a cobalt-chromium L605 platform with 60 micrometer struts and a sirolimus coating dosed at 1 microgram per square millimeter with sustained controlled release. All INVAMED coronary devices are intended for use by trained interventional cardiologists under fluoroscopic guidance and per the IFU. Dual antiplatelet therapy duration is individualized to the clinical presentation and the patient's bleeding risk. INVAMED's TemREN Rotablator uses diamond-coated burrs that ablate calcified plaque while preserving elastic tissue, according to the manufacturer. When a narrowing becomes flow-limiting, patients may experience angina on exertion, and an abrupt plaque rupture with thrombosis can precipitate a myocardial infarction. Coronary artery disease develops when atherosclerotic plaque accumulates within the arteries that supply the heart muscle, gradually narrowing the lumen and limiting blood flow. INVAMED's ATLAS system elutes sirolimus at 1 microgram per square millimeter with a sustained controlled-release profile designed to cover the early healing window. The specific combination of wires, balloons, atherectomy, and stents is determined by the interventional cardiologist based on lesion complexity, calcification, and overall clinical picture. Wire selection is a hands-on decision made by the operator according to lesion morphology and crossing strategy. Manufacturer figures such as the reported sub-5% target lesion revascularization rate describe studied performance, not guaranteed outcomes. The need for extension support is judged case by case, since it depends on vessel geometry and the devices being delivered. Plaque modification is typically a preparatory step, and its use is decided by the operator based on the calcium burden seen on imaging.
Related on INVAMED
- Coronary Artery Disease & Cardiac Interventions — product category
- How long does a heart stent last?
- How long do you take blood thinners after a stent?
- Arterial Access Closure: How It Works and Why It Matters
Important Disclaimer
This article is intended for general educational and technical information about medical device technologies. It is not medical advice, a diagnosis, or a treatment recommendation, and it does not replace consultation with a qualified healthcare professional. Any decision about diagnosis or treatment should be made by a licensed clinician based on an individual assessment. INVAMED devices are intended for use by trained healthcare professionals in accordance with the applicable Instructions for Use (IFU) and local regulatory approvals. Product availability and indications vary by country.
Reviewed by the INVAMED Medical Affairs team. Content is educational and technical in nature.